3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
39
Breast Neoplasms
24
Neoplasms
12
Prostatic Neoplasms
11
Triple Negative Breast Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Pancreatic Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Fanconi Anemia, Complementation Group D1
5
Small Cell Lung Carcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Solid Tumors
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Interventions
Pemetrexed
9
Carboplatin
7
pembrolizumab
6
Cisplatin
6
130-nm albumin-bound paclitaxel
6
Paclitaxel
5
Nivolumab
5
Gemcitabine
5
palbociclib
4
napabucasin
4
durvalumab
4
Fulvestrant
4
Bevacizumab
4
ribociclib
3
osimertinib
3
abemaciclib
3
Mitomycin
3
Irinotecan
3
Fluorouracil
3
Drug Therapy
3
Anastrozole
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pralsetinib
2
patritumab
2
ficlatuzumab
2
exemestane
2
atezolizumab
2
Watchful Waiting
2
Trabectedin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms by Site
×
olaparib
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled